相关实验视频

Updated: May 20, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

在接受前列腺特异性膜抗原正子发射断层扫描的患者中,全身扩散加权成像的附加值

Cheng William Hong¹, Spencer C Behr^1,2, Fei Jiang³

¹Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA.

Journal of clinical medicine

|March 27, 2025

概括

全身扩散加权成像 (DWI) 与前列腺特异性膜抗原 (PSMA) PET扫描相结合,有助于识别PSMA阴性转移性割抵抗性前列腺癌 (mCRPC). 这种成像方法有助于更好的风险分层对接受放射性连接体治疗的患者.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
医疗成像医学成像

背景情况:

转移性割抵抗性前列腺癌 (mCRPC) 患有PSMA阴性疾病的患者在放射性连接体治疗 (RLT) 方面表现较差.
准确识别PSMA阴性疾病对于有效的患者管理和风险分层至关重要.

研究的目的:

评估全身 (WB) 扩散权重成像 (DWI) 对PSMA PET在检测PSMA阴性病变中的附加值.
评估识别PSMA阴性疾病对患者结局的影响.

主要方法:

连续PSMA PET/MRI检查的回顾性审查,包括mCRPC患者的WB DWI.
两个独立的读者评估了14个解剖位置,用于WB DWI和PSMA PET上的病变检测.
读者之间的协议是使用类内相关系数 (ICC) 计算的.

主要成果:

在包括的41名患者中,WB DWI在24%的患者中发现了PSMA阴性病变.
这两种模式都显示出良好的读者间协议,PSMA PET (ICC:0.87) 显示出比DWI (ICC:0.72) 更高的协议.
患有不匹配疾病 (PSMA阴性病变) 的患者的平均整体存活时间为442天,而没有疾病的患者的平均总存活时间为523天,这一差异在统计学上并不显著.

结论:

将WB DWI与PSMA PET集成,可以在mCRPC患者中识别PSMA阴性疾病.
这种结合成像方法有可能影响治疗决策并改善患者管理策略.

关键词:

在PSMA上,PSMA可以在PSMA上进行交易.WB DWI DWI 在线观看扩散权重成像技术的使用.mCRPC 的使用情况.前列腺癌是前列腺癌.

更多相关视频

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET